Portfolio

We have built up an exciting portfolio of investments in high potential businesses across a range of therapeutic areas, technologies, geographies and clinical contexts. 

 

Title

Stage

Technology Area

Company's status

Logo List

News

  • 19 September 2017

    Marinus Pharmaceuticals Announces closing of Public Offering of Common Stock and full exercise of underwriter's option to purchase additional shares

    Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS) ("Marinus" or the "Company") announced the closing of an underwritten public offering of 10,733,334 shares of its common stock for a public offering price of $3.75 per share. This includes the exercise in full by the underwriter of its option to purchase up to 1,400,000 additional shares of common stock. The offering was led by Bain Capital Life Sciences with participation from new and existing investors, raising gross proceeds of approximately $40.3 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by the Company.

  • 15 September 2017

    Marinus Pharmaceuticals Announces Pricing of Public Offering of Common Stock

    Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS) ("Marinus" or the "Company") announced the pricing of an underwritten public offering of 9,333,334 shares of common stock for a public offering price of $3.75 per share. The gross proceeds from the offering are expected to be $35 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by the Company.